Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

• Revenue in USD (TTM)7.00m
• Net income in USD-98.57m
• Incorporated2015
• Employees58.00

• Location
  Kezar Life Sciences Inc4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO 94080-2005United StatesUSA
• Phone+1 (650) 822-5600
• Fax+1 (302) 636-5454
• Websitehttps://kezarlifesciences.com/